Integrum AB (publ) (INTEG-B.ST)
SEK 18.65
(3.04%)
SEK 18.65
(3.04%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 6.42 Million SEK | -18.84% |
| 2022 | 7.91 Million SEK | 1262.6% |
| 2021 | 580.89 Thousand SEK | 19.55% |
| 2020 | 485.91 Thousand SEK | -32.87% |
| 2019 | 723.8 Thousand SEK | -48.53% |
| 2018 | 1.4 Million SEK | -40.41% |
| 2017 | 2.35 Million SEK | -28.78% |
| 2016 | 3.31 Million SEK | -14.83% |
| 2015 | 3.89 Million SEK | 256.88% |
| 2014 | 1.09 Million SEK | -15.5% |
| 2013 | 1.29 Million SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 6.03 Million SEK | -6.01% |
| 2023 FY | 6.42 Million SEK | -18.84% |
| 2023 Q1 | 7.55 Million SEK | -4.6% |
| 2023 Q4 | 6.42 Million SEK | -5.6% |
| 2023 Q3 | 6.8 Million SEK | -5.24% |
| 2023 Q2 | 7.18 Million SEK | -4.9% |
| 2022 Q2 | 106 Thousand SEK | -74.27% |
| 2022 Q4 | 7.91 Million SEK | 18745.89% |
| 2022 FY | 7.91 Million SEK | 1262.6% |
| 2022 Q1 | 412 Thousand SEK | -29.07% |
| 2022 Q3 | 42 Thousand SEK | -60.38% |
| 2021 Q3 | 799 Thousand SEK | -23.61% |
| 2021 Q2 | 1.04 Million SEK | 147.55% |
| 2021 Q1 | 422.53 Thousand SEK | -13.04% |
| 2021 FY | 580.89 Thousand SEK | 19.55% |
| 2021 Q4 | 580.89 Thousand SEK | -27.3% |
| 2020 Q3 | 594.29 Thousand SEK | -15.42% |
| 2020 FY | 485.91 Thousand SEK | -32.87% |
| 2020 Q4 | 485.91 Thousand SEK | -18.24% |
| 2020 Q2 | 702.67 Thousand SEK | -2.92% |
| 2020 Q1 | 723.8 Thousand SEK | 0.0% |
| 2019 Q4 | 723.8 Thousand SEK | -24.62% |
| 2019 FY | 723.8 Thousand SEK | -48.53% |
| 2019 Q1 | 1.16 Million SEK | -16.95% |
| 2019 Q2 | 929.43 Thousand SEK | -20.41% |
| 2019 Q3 | 960.21 Thousand SEK | 3.31% |
| 2018 Q4 | 1.4 Million SEK | -14.49% |
| 2018 FY | 1.4 Million SEK | -40.41% |
| 2018 Q1 | 2.12 Million SEK | -10.1% |
| 2018 Q2 | 1.88 Million SEK | -11.24% |
| 2018 Q3 | 1.64 Million SEK | -12.66% |
| 2017 FY | 2.35 Million SEK | -28.78% |
| 2017 Q2 | 2.83 Million SEK | -7.75% |
| 2017 Q1 | 3.07 Million SEK | -7.19% |
| 2017 Q3 | 2.59 Million SEK | -8.4% |
| 2017 Q4 | 2.35 Million SEK | -9.18% |
| 2016 Q4 | 3.31 Million SEK | -6.72% |
| 2016 Q3 | 3.55 Million SEK | 0.0% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 FY | 3.31 Million SEK | -14.83% |
| 2015 FY | 3.89 Million SEK | 256.88% |
| 2015 Q4 | 3.89 Million SEK | 0.0% |
| 2014 FY | 1.09 Million SEK | -15.5% |
| 2013 FY | 1.29 Million SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.602% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.602% |
| Arcoma AB | 3.87 Million SEK | -65.871% |
| Bactiguard Holding AB (publ) | 233.09 Million SEK | 97.244% |
| BICO Group AB (publ) | 1.85 Billion SEK | 99.653% |
| Boule Diagnostics AB (publ) | 166.1 Million SEK | 96.132% |
| CellaVision AB (publ) | 64.7 Million SEK | 90.071% |
| Clinical Laserthermia Systems AB (publ) | 454 Thousand SEK | -1315.018% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.8 Million SEK | -256.899% |
| Duearity AB (publ) | 10.58 Million SEK | 39.291% |
| Dignitana AB (publ) | 19.1 Million SEK | 66.373% |
| Episurf Medical AB (publ) | 5.2 Million SEK | -23.542% |
| Getinge AB (publ) | 8.07 Billion SEK | 99.92% |
| Scandinavian Real Heart AB (Publ) | 8.24 Million SEK | 22.128% |
| Iconovo AB (publ) | 7.72 Million SEK | 16.838% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -3018.171% |
| Mentice AB (publ) | 9.55 Million SEK | 32.78% |
| OssDsign AB (publ) | 3.15 Million SEK | -103.942% |
| Paxman AB (publ) | 13.57 Million SEK | 52.659% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 20.73 Million SEK | 69.012% |
| SciBase Holding AB (publ) | 6.79 Million SEK | 5.485% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 31.78 Million SEK | 79.791% |
| Sedana Medical AB (publ) | 4.3 Million SEK | -49.191% |
| Senzime AB (publ) | 11.46 Million SEK | 43.982% |
| SpectraCure AB (publ) | 6.71 Million SEK | 4.359% |
| Stille AB | 62.94 Million SEK | 89.793% |
| Vitrolife AB (publ) | 2.08 Billion SEK | 99.692% |
| Xvivo Perfusion AB (publ) | 31.43 Million SEK | 79.565% |